CABA logo

CABA
Cabaletta Bio Inc

3,757
Mkt Cap
$601.67M
Volume
2.24M
52W High
$4.23
52W Low
$1.26
PE Ratio
-1.85
CABA Fundamentals
Price
$3.65
Prev Close
$3.69
Open
$3.70
50D MA
$3.20
Beta
1.72
Avg. Volume
1.96M
EPS (Annual)
-$2.10
P/B
3.93
Rev/Employee
$0.00
$68.49
Loading...
Loading...
News
all
press releases
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
News Placeholder
More News
News Placeholder
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
News Placeholder
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial
Data from a higher dose population is now expected in the second half of 2026.
News Placeholder
Cabaletta Bio (NASDAQ:CABA) Receives "Overweight" Rating from Cantor Fitzgerald
Cantor Fitzgerald reissued an 'overweight' rating and issued a $30.00 price target on shares of Cabaletta Bio in a research report on Monday...
News Placeholder
Stock Traders Buy High Volume of Call Options on Cabaletta Bio (NASDAQ:CABA)
Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) saw unusually large options trading on Wednesday. Stock investors acquired 11,001 call options on the stock. This is an increase of 756% compared...
News Placeholder
Wall Street Zen Downgrades Cabaletta Bio (NASDAQ:CABA) to Sell
Wall Street Zen downgraded shares of Cabaletta Bio from a "hold" rating to a "sell" rating in a report on Saturday...
News Placeholder
First Patients Dosed with Cabaletta Bios Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.s (Cabaletta Bio or Cabaletta) (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has been infused into the first two patients using drug...
News Placeholder
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Moderate Buy" by Analysts
Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One...
News Placeholder
Cabaletta Bio, Inc. $CABA Position Raised by JPMorgan Chase & Co.
JPMorgan Chase & Co. raised its stake in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 565.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional...
News Placeholder
Q1 EPS Estimates for Cabaletta Bio Raised by HC Wainwright
Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Research analysts at HC Wainwright boosted their Q1 2026 EPS estimates for shares of Cabaletta Bio in a research note issued on Wednesday, April 1st. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.3...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available